Sarcoidosis - Market Insight, Epidemiology and Market Forecast - 2028

Date: January 1, 2019
Pages: 100
Price:
US$ 6,250.00
License [?]:
Publisher: DelveInsight
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S5365E92D1FEN
Leaflet:

Download PDF Leaflet

Sarcoidosis - Market Insight, Epidemiology and Market Forecast - 2028
This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Sarcoidosis - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Sarcoidosis epidemiology and market outlook for the 7MM.

MARKETS COVERED
  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2016-2028

Sarcoidosis Understanding and Treatment Algorithm

The market report provides the overview of the Sarcoidosis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Sarcoidosis Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Sarcoidosis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Sarcoidosis Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Sarcoidosis Market Outlook

The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Sarcoidosis market.
Sarcoidosis Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Sarcoidosis Report Insights
  • Patient Population in Sarcoidosis
  • Therapeutic Approaches in Sarcoidosis
  • Sarcoidosis Pipeline Analysis
  • Sarcoidosis Market Size and Trends
  • Sarcoidosis Market Opportunities
  • Impact of upcoming Therapies in Sarcoidosis
Sarcoidosis Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Sarcoidosis Report Assessment
  • Current Treatment Practices in Sarcoidosis
  • Unmet Needs in Sarcoidosis
  • Market Attractiveness
  • Market Drivers and Barriers
KEY BENEFITS
  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Sarcoidosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Sarcoidosis market
  • To understand the future market competition in the Sarcoidosis market.
1. REPORT INTRODUCTION

2. SARCOIDOSIS MARKET OVERVIEW AT A GLANCE

2.1. Market Share Distribution of Sarcoidosis in 2016
2.2. Market Share Distribution of Sarcoidosis in 2028

3. DISEASE BACKGROUND AND OVERVIEW: SARCOIDOSIS

3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Sarcoidosis in 7MM
4.3. Total Prevalent Patient Population of Sarcoidosis in 7MM – By Countries

5. EPIDEMIOLOGY OF SARCOIDOSIS BY COUNTRIES

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Prevalent/Incident Cases of the Sarcoidosis
  5.1.3. Sub-Type Specific cases of the Sarcoidosis
  5.1.4. Sex- Specific Cases of the Sarcoidosis
  5.1.5. Diagnosed Cases of the Sarcoidosis
  5.1.6. Treatable Cases of the Sarcoidosis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
  5.4.1. Assumptions and Rationale
  5.4.2. Prevalent/Incident Cases of the Sarcoidosis
  5.4.3. Sub-Type Specific cases of the Sarcoidosis
  5.4.4. Sex- Specific Cases of the Sarcoidosis
  5.4.5. Diagnosed Cases of the Sarcoidosis
  5.4.6. Treatable Cases of the Sarcoidosis
5.5. France
  5.5.1. Assumptions and Rationale
  5.5.2. Prevalent/Incident Cases of the Sarcoidosis
  5.5.3. Sub-Type Specific cases of the Sarcoidosis
  5.5.4. Sex- Specific Cases of the Sarcoidosis
  5.5.5. Diagnosed Cases of the Sarcoidosis
  5.5.6. Treatable Cases of the Sarcoidosis
5.6. Italy
  5.6.1. Assumptions and Rationale
  5.6.2. Prevalent/Incident Cases of the Sarcoidosis
  5.6.3. Sub-Type Specific cases of the Sarcoidosis
  5.6.4. Sex- Specific Cases of the Sarcoidosis
  5.6.5. Diagnosed Cases of the Sarcoidosis
  5.6.6. Treatable Cases of the Sarcoidosis
5.7. Spain
  5.7.1. Assumptions and Rationale
  5.7.2. Prevalent/Incident Cases of the Sarcoidosis
  5.7.3. Sub-Type Specific cases of the Sarcoidosis
  5.7.4. Sex- Specific Cases of the Sarcoidosis
  5.7.5. Diagnosed Cases of the Sarcoidosis
  5.7.6. Treatable Cases of the Sarcoidosis
5.8. United Kingdom
  5.8.1. Assumptions and Rationale
  5.8.2. Prevalent/Incident Cases of the Sarcoidosis
  5.8.3. Sub-Type Specific cases of the Sarcoidosis
  5.8.4. Sex- Specific Cases of the Sarcoidosis
  5.8.5. Diagnosed Cases of the Sarcoidosis
  5.8.6. Treatable Cases of the Sarcoidosis
5.9. Japan
  5.9.1. Assumptions and Rationale
  5.9.2. Prevalent/Incident Cases of the Sarcoidosis
  5.9.3. Sub-Type Specific cases of the Sarcoidosis
  5.9.4. Sex- Specific Cases of the Sarcoidosis
  5.9.5. Diagnosed Cases of the Sarcoidosis
  5.9.6. Treatable Cases of the Sarcoidosis

6. CURRENT TREATMENT & MEDICAL PRACTICES

6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. UNMET NEEDS OF THE SARCOIDOSIS

8. MARKETED THERAPIES

8.1. Drug A: Company
  8.1.1. Drug Description
  8.1.2. Mechanism of Action
  8.1.3. Regulatory Milestones
  8.1.4. Advantages & Disadvantages
  8.1.5. Product Profile
8.2. Drug B: Company
  8.2.1. Drug Description
  8.2.2. Mechanism of Action
  8.2.3. Regulatory Milestones
  8.2.4. Advantages & Disadvantages
  8.2.5. Product Profile

9. PIPELINE THERAPIES – AT A GLANCE

10. KEY CROSS COMPETITION

11. EMERGING THERAPIES FOR SARCOIDOSIS

11.1. Drug C: Company
  11.1.1. Drug Description
  11.1.2. Clinical Trials Details
  11.1.3. Safety and Efficacy Profile
  11.1.4. Advantages & Disadvantages
  11.1.5. Pipeline Development Activities
  11.1.6. Product Profile
11.2. Drug D: Company
  11.2.1. Drug Description
  11.2.2. Clinical Trials Details
  11.2.3. Safety and Efficacy Profile
  11.2.4. Advantages & Disadvantages
  11.2.5. Pipeline Development Activities
  11.2.6. Product Profile

12. SARCOIDOSIS: 7MM MARKET ANALYSIS

12.1. 7MM Market Size of Sarcoidosis
12.2. 7MM Percentage Share of drugs marketed for Sarcoidosis
12.3. 7MM Market Sales of Sarcoidosis by Products

13. SARCOIDOSIS: COUNTRY-WISE MARKET ANALYSIS

13.1. United States
  13.1.1. Market Size of Sarcoidosis in United States
  13.1.2. Percentage Share of drugs marketed for Sarcoidosis in United States
  13.1.3. Market Sales of Sarcoidosis by Products in United States
  13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
  13.2.1. Germany
    13.2.1.1. Market Size of Sarcoidosis in Germany
    13.2.1.2. Percentage Share of drugs marketed for Sarcoidosis in Germany
    13.2.1.3. Market Sales of Sarcoidosis by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.2. France
    13.2.2.1. Market Size of Sarcoidosis in France
    13.2.2.2. Percentage Share of drugs marketed for Sarcoidosis in France
    13.2.2.3. Market Sales of Sarcoidosis by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.3. Italy
    13.2.3.1. Market Size of Sarcoidosis in Italy
    13.2.3.2. Percentage Share of drugs marketed for Sarcoidosis in Italy
    13.2.3.3. Market Sales of Sarcoidosis by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.4. Spain
    13.2.4.1. Market Size of Sarcoidosis in Spain
    13.2.4.2. Percentage Share of drugs marketed for Sarcoidosis in Spain
    13.2.4.3. Market Sales of Sarcoidosis by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.5. United Kingdom
    13.2.5.1. Market Size of Sarcoidosis in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Sarcoidosis in United Kingdom
    13.2.5.3. Market Sales of Sarcoidosis by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
  13.3.1. Market Size of Sarcoidosis in Japan
  13.3.2. Percentage Share of drugs marketed for Sarcoidosis in Japan
  13.3.3. Market Sales of Sarcoidosis by Products in Japan
  13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. MARKET DRIVERS

15. MARKET BARRIERS

16. APPENDIX

17. REPORT METHODOLOGY

17.1. Sources

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

Indication Specific


LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Sarcoidosis in 7MM
Table 2: Total Prevalent/Incident Cases of the Sarcoidosis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Sarcoidosis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Sarcoidosis in United States (2016-2028)
Table 5: Sex- Specific Cases of the Sarcoidosis in United States (2016-2028)
Table 6: Diagnosed Cases of the Sarcoidosis in United States (2016-2028)
Table 7: Treatable Cases of the Sarcoidosis in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Sarcoidosis in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Sarcoidosis in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Sarcoidosis in Germany (2016-2028)
Table 11: Diagnosed Cases of the Sarcoidosis in Germany (2016-2028)
Table 12: Treatable Cases of the Sarcoidosis in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Sarcoidosis in France (2016-2028)
Table 14: Sub-Type Specific cases of the Sarcoidosis in France (2016-2028)
Table 15: Sex- Specific Cases of the Sarcoidosis in France (2016-2028)
Table 16: Diagnosed Cases of the Sarcoidosis in France (2016-2028)
Table 17: Treatable Cases of the Sarcoidosis in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Sarcoidosis in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Sarcoidosis in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Sarcoidosis in Italy (2016-2028)
Table 21: Diagnosed Cases of the Sarcoidosis in Italy (2016-2028)
Table 22: Treatable Cases of the Sarcoidosis in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Sarcoidosis in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Sarcoidosis in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Sarcoidosis in Spain (2016-2028)
Table 26: Diagnosed Cases of the Sarcoidosis in Spain (2016-2028)
Table 27: Treatable Cases of the Sarcoidosis in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Sarcoidosis in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Sarcoidosis in UK (2016-2028)
Table 30: Sex- Specific Cases of the Sarcoidosis in UK (2016-2028)
Table 31: Diagnosed Cases of the Sarcoidosis in UK (2016-2028)
Table 32: Treatable Cases of the Sarcoidosis in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Sarcoidosis in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Sarcoidosis in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Sarcoidosis in Japan (2016-2028)
Table 36: Diagnosed Cases of the Sarcoidosis in Japan (2016-2028)
Table 37: Treatable Cases of the Sarcoidosis in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Sarcoidosis in USD MM (2016-2028)
Table 42:7MM- Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Sarcoidosis in USD MM (2016-2028)
Table 45: United States-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Sarcoidosis in USD MM (2016-2028)
Table 48: Germany-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Sarcoidosis in USD MM (2016-2028)
Table 51: France-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Sarcoidosis in USD MM (2016-2028)
Table 54: Italy-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Sarcoidosis in USD MM (2016-2028)
Table 57: Spain-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Sarcoidosis in USD MM (2016-2028)
Table 60:UK-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Sarcoidosis in USD MM (2016-2028)
Table 63: Japan-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Sarcoidosis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Sarcoidosis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Sarcoidosis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Sarcoidosis in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Sarcoidosis in United States (2016-2028)
Figure 6: Diagnosed Cases of the Sarcoidosis in United States (2016-2028)
Figure 7: Treatable Cases of the Sarcoidosis in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Sarcoidosis in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Sarcoidosis in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Sarcoidosis in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Sarcoidosis in Germany (2016-2028)
Figure 12: Treatable Cases of the Sarcoidosis in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Sarcoidosis in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Sarcoidosis in France (2016-2028)
Figure 15: Sex- Specific Cases of the Sarcoidosis in France (2016-2028)
Figure 16: Diagnosed Cases of the Sarcoidosis in France (2016-2028)
Figure 17: Treatable Cases of the Sarcoidosis in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Sarcoidosis in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Sarcoidosis in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Sarcoidosis in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Sarcoidosis in Italy (2016-2028)
Figure 22: Treatable Cases of the Sarcoidosis in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Sarcoidosis in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Sarcoidosis in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Sarcoidosis in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Sarcoidosis in Spain (2016-2028)
Figure 27: Treatable Cases of the Sarcoidosis in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Sarcoidosis in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Sarcoidosis in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Sarcoidosis in UK (2016-2028)
Figure 31: Diagnosed Cases of the Sarcoidosis in UK (2016-2028)
Figure 32: Treatable Cases of the Sarcoidosis in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Sarcoidosis in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Sarcoidosis in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Sarcoidosis in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Sarcoidosis in Japan (2016-2028)
Figure 37: Treatable Cases of the Sarcoidosis in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 42:7MM- Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 45: United States-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 48: Germany-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 51: France-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 54: Italy-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 57: Spain-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 60:UK-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Sarcoidosis in USD MM (2016-2028)
Figure 63: Japan-Market Share Sarcoidosis by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Sarcoidosis by Therapies in USD MM (2016-2028)
Skip to top


Ask Your Question

Sarcoidosis - Market Insight, Epidemiology and Market Forecast - 2028
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: